NDC 1308
Alternative Names: NDC-1308; NDC-1308 (MC1); NDC-1308 (MC2)Latest Information Update: 28 Jul 2024
At a glance
- Originator ENDECE
- Class Anti-inflammatories; Antidementias; Antivirals; Estradiol congeners; Estrenes; Eye disorder therapies; Small molecules
- Mechanism of Action Estrogen receptor agonists; Hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Demyelinating disorders; Multiple sclerosis; Neuromyelitis optica
Highest Development Phases
- No development reported Alzheimer's disease; COVID 2019 infections; Demyelinating disorders; Multiple sclerosis; Neuromyelitis optica; Niemann-Pick disease type C; Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Inhalation)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Niemann-Pick-disease-type-C in USA (Intranasal)
- 28 Mar 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Intranasal)